Sections of Cardiovascular Medicine (T.A., K.J., V.S.R., J.M.T.).
Section of Heart Failure and Cardiac Transplantation, The Cleveland Clinic, OH (W.H.W.T.).
Circulation. 2018 May 8;137(19):2016-2028. doi: 10.1161/CIRCULATIONAHA.117.030112. Epub 2018 Jan 19.
Worsening renal function (WRF) in the setting of aggressive diuresis for acute heart failure treatment may reflect renal tubular injury or simply indicate a hemodynamic or functional change in glomerular filtration. Well-validated tubular injury biomarkers, -acetyl-β-d-glucosaminidase, neutrophil gelatinase-associated lipocalin, and kidney injury molecule 1, are now available that can quantify the degree of renal tubular injury. The ROSE-AHF trial (Renal Optimization Strategies Evaluation-Acute Heart Failure) provides an experimental platform for the study of mechanisms of WRF during aggressive diuresis for acute heart failure because the ROSE-AHF protocol dictated high-dose loop diuretic therapy in all patients. We sought to determine whether tubular injury biomarkers are associated with WRF in the setting of aggressive diuresis and its association with prognosis.
Patients in the multicenter ROSE-AHF trial with baseline and 72-hour urine tubular injury biomarkers were analyzed (n=283). WRF was defined as a ≥20% decrease in glomerular filtration rate estimated with cystatin C.
Consistent with protocol-driven aggressive dosing of loop diuretics, participants received a median 560 mg IV furosemide equivalents (interquartile range, 300-815 mg), which induced a urine output of 8425 mL (interquartile range, 6341-10 528 mL) over the 72-hour intervention period. Levels of -acetyl-β-d-glucosaminidase and kidney injury molecule 1 did not change with aggressive diuresis (both >0.59), whereas levels of neutrophil gelatinase-associated lipocalin decreased slightly (-8.7 ng/mg; interquartile range, -169 to 35 ng/mg; <0.001). WRF occurred in 21.2% of the population and was not associated with an increase in any marker of renal tubular injury: neutrophil gelatinase-associated lipocalin (=0.21), -acetyl-β-d-glucosaminidase (=0.46), or kidney injury molecule 1 (=0.22). Increases in neutrophil gelatinase-associated lipocalin, -acetyl-β-d-glucosaminidase, and kidney injury molecule 1 were paradoxically associated with improved survival (adjusted hazard ratio, 0.80 per 10 percentile increase; 95% confidence interval, 0.69-0.91; =0.001).
Kidney tubular injury does not appear to have an association with WRF in the context of aggressive diuresis of patients with acute heart failure. These findings reinforce the notion that the small to moderate deteriorations in renal function commonly encountered with aggressive diuresis are dissimilar from traditional causes of acute kidney injury.
急性心力衰竭治疗中积极利尿时肾功能恶化(WRF)可能反映肾小管损伤,或者仅表明肾小球滤过的血流动力学或功能变化。现在有经过良好验证的肾小管损伤生物标志物 - 乙酰-β-D-氨基葡萄糖苷酶、中性粒细胞明胶酶相关脂质运载蛋白和肾损伤分子 1,可定量评估肾小管损伤程度。ROSE-AHF 试验(肾脏优化策略评估-急性心力衰竭)为研究急性心力衰竭积极利尿时 WRF 的机制提供了一个实验平台,因为 ROSE-AHF 方案规定所有患者均接受大剂量袢利尿剂治疗。我们试图确定在积极利尿和其与预后的关联中,肾小管损伤生物标志物是否与 WRF 相关。
对多中心 ROSE-AHF 试验中具有基线和 72 小时尿液肾小管损伤生物标志物的患者进行分析(n=283)。WRF 定义为胱抑素 C 估计肾小球滤过率下降≥20%。
与方案驱动的积极袢利尿剂剂量一致,参与者接受中位数为 560mg IV 呋塞米等效物(四分位距,300-815mg),在 72 小时干预期间诱导尿量为 8425mL(四分位距,6341-10528mL)。在积极利尿过程中,-乙酰-β-D-氨基葡萄糖苷酶和肾损伤分子 1 的水平没有变化(均>0.59),而中性粒细胞明胶酶相关脂质运载蛋白水平略有下降(-8.7ng/mg;四分位距,-169 至 35ng/mg;<0.001)。人群中发生 WRF 的比例为 21.2%,与任何肾小管损伤标志物的增加均无关:中性粒细胞明胶酶相关脂质运载蛋白(=0.21)、-乙酰-β-D-氨基葡萄糖苷酶(=0.46)或肾损伤分子 1(=0.22)。中性粒细胞明胶酶相关脂质运载蛋白、-乙酰-β-D-氨基葡萄糖苷酶和肾损伤分子 1 的增加与生存改善呈相反关系(调整后的危险比,每增加 10%分位数增加 0.80;95%置信区间,0.69-0.91;=0.001)。
在急性心力衰竭患者积极利尿的情况下,肾脏管状损伤似乎与 WRF 无关。这些发现强化了这样的观念,即积极利尿时肾功能的小到中度恶化与传统的急性肾损伤原因不同。